Live Breaking News & Updates on Leverage Access

Stay updated with breaking news from Leverage access. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases


Home / Top News / Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases
Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases
Collaboration will Leverage Access to the NURTuRE Patient Biobank and Evotec’s PanHunter Multi-Omics Platform to Characterize Molecular Drivers, Identify and Validate Novel Targets and Drive Patient Stratification Strategies in Kidney Disease
Collaboration Will Focus on Polycystic Kidney Disease (PKD), Lupus Nephritis, IgA Nephropathy and Other Primary Glomerular Diseases
VANCOUVER, British Columbia and SEATTLE, March 01, 2021 (GLOBE NEWSWIRE) Chinook Therapeutics, Inc. (NASDAQ: KDNY) and Evotec SE today announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases. Ba ....

United Kingdom , British Columbia , Andrew King , Noopur Liffick , National Unified Renal Translational Research Enterprise , Boehringer Ingelheim , Chinook Therapeutics Inc , Bristol Myers Squibb , Investor Relations Corporate Communications , Novo Nordisk , Leverage Access , Panhunter Multi Omics Platform , Characterize Molecular Drivers , Validate Novel Targets , Drive Patient Stratification Strategies , Will Focus , Polycystic Kidney Disease , Lupus Nephritis , Iga Nephropathy , Chinook Therapeutics , Renal Discovery , Translational Medicine , Cord Dohrmann , Chief Scientific Officer , Forward Looking Statements , Investor Relations ,